首页> 外文OA文献 >Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation
【2h】

Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation

机译:HLA匹配的同种异体干细胞同种异体干细胞移植后长期生存和晚期事件,与强度降低的条件相比,与清髓相比,清髓性:代表欧洲血液和骨髓移植小组急性白血病工作组的报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BACKGROUND: Myeloablative (MAC) and reduced-intensity conditioning (RIC) are established approaches for allogeneic stem cell transplantation (SCT) in acute myeloid leukemia (AML). Most deaths after MAC occur within the first 2 years after SCT, while patients surviving leukemia-free for 2 years can expect a favorable long-term outcome. However, there is paucity of data on the long-term outcome (beyond 10 years) and the pattern of late events following RIC due to the relative recent introduction of this approach. METHODS: We analyzed long-term outcomes in a cohort of 1423 AML patients, age /=50 years, after SCT from HLA-matched siblings, during the years 1997-2005, median follow-up 8.3 years (0.1-17). RESULTS: The 10-year leukemia-free survival (LFS) was 31 % (95CI, 27-35) and 32 % (28-35) after MAC and RIC, respectively (P = 0.57). The 10-year GVHD/ relapse-free survival (GRFS), a surrogate for quality of life was 22 % (18-25) and 21 % (18-24), respectively (P = 0.79). The 10-year non-relapse mortality (NRM) was higher and relapse rate was lower after MAC, throughout the early and late post-transplant course. The 10-year LFS among 584 patients surviving leukemia-free 2 years after SCT was 71 % (65-76) and 73 % (67-78) after MAC and RIC, respectively (P = 0.76). Advanced leukemia at SCT was the major predictor of LFS subsequent to the 2-year landmark. Relapse was the major cause of late death after both regimens; however, NRM and in particular chronic graft-versus-host disease and second cancers were more common causes of late death after MAC. CONCLUSIONS: Long-term LFS and GRFS are similar after RIC and MAC. Most events after RIC or MAC occur within the first 2 years after SCT. Patients who are leukemia-free 2 years after SCT can expect similar good subsequent outcome after both approaches.
机译:背景:清髓(MAC)和强度降低调节(RIC)是在急性髓细胞性白血病(AML)中进行同种异体干细胞移植(SCT)的既定方法。 MAC后的大多数死亡发生在SCT后的前2年,而无白血病生存2年的患者可以期待长期的良好结局。但是,由于相对较近的这种方法的引入,有关RIC的长期结果(超过10年)和晚期事件的模式的数据很少。方法:我们分析了1997年至2005年间从HLA匹配的同胞进行SCT后,年龄≥50岁的1423例AML患者的长期结果,中位随访时间为8。3年(0.1-17岁)。结果:MAC和RIC后10年无白血病生存率(LFS)分别为31%(95CI,27-35)和32%(28-35)(P = 0.57)。 10年GVHD /无复发生存率(GRFS)是生活质量的替代指标,分别为22%(18-25)和21%(18-24)(P = 0.79)。在整个移植后的早期和晚期,MAC后的10年非复发死亡率(NRM)较高,复发率较低。在584例SCT术后无白血病存活的584名患者中,10年LFS分别为MAC和RIC后的71%(65-76)和73%(67-78)(P = 0.76)。 SCT晚期白血病是2年标志性事件后LFS的主要预测指标。两种疗法后复发都是导致晚期死亡的主要原因。然而,NRM,尤其是慢性移植物抗宿主病和继发性癌症是MAC术后晚期死亡的更常见原因。结论:RIC和MAC后,长期LFS和GRFS相似。 RIC或MAC后的大多数事件发生在SCT之后的前2年内。 SCT 2年后无白血病的患者在两种方法后均有望获得类似的良好后续结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号